Fujimura T, Shibata H, Maekawa I, Furusawa S, Kawauchi H, Sasaki K, Takayanagi Y
Cancer Research Institute, Tohoku College of Pharmacy, Sendai, Japan.
Jpn J Pharmacol. 1990 Dec;54(4):464-7. doi: 10.1254/jjp.54.464.
Cytotoxic effect in vitro and antitumor effect in vivo of doxorubicin (DOX) combined with cepharanthine were investigated on DOX-resistant murine P388 leukemia (P388/R) cells. Cepharanthine was minimally cytotoxic in the cell line, but reversed DOX-resistance in a dose-related manner in P388/R cells. The administration of cepharanthine to mice bearing the P388 leukemia enhanced the antitumor activity of DOX. These results indicate that cepharanthine is an effective agent to reverse DOX-resistant cells.
